Literature DB >> 21732742

Nuclear MASPIN expression relates to a better prognosis in elderly patients with laryngeal carcinoma.

Gino Marioni1, Stella Blandamura, Marco Lionello, Luciano Giacomelli, Claudia Staffieri, Elena Fasanaro, Enzo Manzato, Alberto Staffieri.   

Abstract

CONCLUSION: MASPIN subcellular location can be considered a prognostic marker that is potentially useful for identifying elderly patients with laryngeal carcinoma at higher risk of early loco-regional recurrence, who may benefit from more aggressive therapy. In a targeted treatment setting, re-activated nuclear MASPIN in combination with anti-angiogenic and/or cytotoxic drugs may be effective in treating laryngeal carcinoma in elderly patients.
OBJECTIVES: Aging is associated with molecular, cellular, and physiological changes that influence carcinogenesis and cancer growth. MASPIN has multifaceted anti-tumor effects and available evidence supports the hypothesis that its subcellular location influences its functions. The aim of the present study was to firstly assess the potential prognostic role of subcellular MASPIN location in elderly patients (>65 years old) with laryngeal carcinoma.
METHODS: MASPIN expression and location were immunohistochemically determined in 68 consecutive elderly patients with laryngeal carcinoma.
RESULTS: Nodal involvement and pathological stage correlated strongly with the prognosis for laryngeal carcinomas in elderly patients, in terms of disease recurrence rate and disease-free survival. The loco-regional recurrence rate was significantly lower (p = 0.041) and the disease-free survival after treatment was significantly longer (p = 0.045) in cases with a nuclear pattern of MASPIN subcellular expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732742     DOI: 10.3109/00016489.2011.599817

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  4 in total

1.  Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23-H1 and CD105) and pN+ status.

Authors:  Andrea Lovato; Gino Marioni; Enzo Manzato; Claudia Staffieri; Luciano Giacomelli; Giovanni Ralli; Alberto Staffieri; Stella Blandamura
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-04       Impact factor: 2.503

2.  Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer.

Authors:  Xing Wang; Yang Wang; Shaolei Li; Bin Dong; Qingfeng Zheng; Shi Yan; Yuanyuan Ma; Jianzhi Zhang; Jian Fang; Nan Wu; Huijuan Wu; Yue Yang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

3.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

4.  The roles of maspin expression in gastric cancer: a meta- and bioinformatics analysis.

Authors:  Hua-Chuan Zheng; Bao-Cheng Gong
Journal:  Oncotarget       Date:  2017-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.